high levels of neutralizing antibodies

Moderna indicates durable immunity. (NASDAQ:MRNA) says participants in the Phase 1 study led by the National Institute of Allergy and Infectious Diseases of mRNA-1273, its COVID-19 vaccine candidate, retained high levels of neutralizing antibodies through 119 days following the first vaccination and 90 days following the second vaccination.

  • The interim Phase 1 data suggests that mRNA-1273 “can generate durable neutralizing antibodies across all age groups including in older and elderly adults,” Moderna Chief Medical Officer Tal Zaks says. “These data give us further optimism to expect that the high level of efficacy recently demonstrated by mRNA-1273 to prevent COVID-19 disease will be durable.”
  • The company reaffirms it expects to have 100M-125M doses available globally in Q1 2021, including 85M-100M in the U.S. and 15M-25M available outside the U.S.

Moderna indicates durable immunity.

Moderna said that the Q1 doses are included in the 500 million doses it expects to make worldwide in 2021.

The vaccine maker would have nearly 20 million doses available by end of this month in the U.S.

Moderna disclosed that results from an early-stage study show that the volunteers who received a jab of mRNA-1273 vaccine retained high levels of binding and neutralizing antibodies, which declined slightly over time, after the first dose, but remained elevated three months after a booster dose.

Moderna indicates durable immunity.

Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273. The amendment brings the total number of doses secured by Israel to 6 million. The vaccine is currently awaiting review for an emergency use authorization in the U.S., and has been submitted for approval in Europe. The company has initiated the rolling regulatory review process with the Ministry of Health in Israel, it said in a statement. The vaccine has proven to have 94% efficacy in a preliminary analysis of a Phase 3 trial conducted on 196 cases. The trial involves more than 30,000 participants and is being conducted with the NIAID part of the NIH and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. Moderna is also working to scale up manufacturing and aims to deliver about 500 million doses a year and up to 1 billion doses a year starting in 2021. Shares were slightly lower premarket, but have gained 704% in the year to date, while the JSPDR S&P 500 Biotech ETF has gained 41% and the S&P 500 [ has gained 13%.

SmallCapNewsAlert

Latest news

Please follow and like us:

By Editors